Premium
De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients
Author(s) -
Idowu Michael O.,
Chhatrala Ravi,
Siddiqui M. Bilal,
Driscoll Carolyn,
Stravitz R. Todd,
Sanyal Arun J.,
Bhati Chandra,
Sargeant Carol,
Luketic Velimir A.,
Sterling Richard K.,
Contos Melissa,
Matherly Scott,
Puri Puneet,
Siddiqui M. Shadab
Publication year - 2015
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.24223
Subject(s) - medicine , steatosis , liver transplantation , gastroenterology , fatty liver , transplantation , disease
Nonalcoholic fatty liver disease is associated with cardiovascular disease (CVD) in the general population. Despite a high prevalence of de novo hepatic steatosis after liver transplantation (LT), there are no data exploring the association between hepatic steatosis after LT and atherogenic risk. The aim of the study was to explore the impact of hepatic steatosis on serum atherogenic markers in liver transplantation recipients (LTRs). Biomarkers of CVD risk were compared in 89 LTRs with no known history of dyslipidemia, ischemic heart disease, or graft cirrhosis. To avoid potential confounders, LTRs on oral hypoglycemic agents, exogenous insulin, corticosteroids, or lipid‐lowering therapy were excluded. Only patients for whom histological assessment was available after LT were included in the study. Thirty‐five LTRs had de novo hepatic steatosis after LT, whereas 54 did not. Both cohorts were similar with regards to age, sex, ethnicity, and follow‐up from LT. Additionally, the traditional lipid profile was similar between the 2 cohorts. LTRs with hepatic steatosis had higher serum concentrations of small‐dense low‐density lipoprotein cholesterol (sdLDL‐C; 34.8 ± 16.9 versus 22.7 ± 11.2 mg/dL; P < 0.001), sdLDL‐C to low‐density lipoprotein cholesterol ratio (32.6 ± 11.6 versus 24.6 ± 10.2; P < 0.01), small‐dense low‐density lipoprotein particle concentration (sdLDL‐P; 770 ± 440 versus 486 ± 402 nmol/L; P < 0.01), very low density lipoprotein particle concentration (VLDL‐P; 7.90 ± 7.91 versus 3.86 ± 3.18 nmol/L; P < 0.01), and very low density lipoprotein size (VLDL‐size; 51.9 ± 6.4 versus 48.7 ± 6.3 nm; P = 0.06). LTRs with hepatic steatosis had higher serum insulin concentrations (27.8 ± 41.8 versus 11.7 ± 7.8 uU/mL; P < 0.01) but similar fasting glucose and hemoglobin A1c. Steatosis grade was directly related to sdLDL‐C, sdLDL‐P, insulin, VLDL‐P, and VLDL‐size. In multivariate analysis, the association between steatosis grade and sdLDL‐C (β = 0.03; P = 0.029), VLDL‐size (β = 0.316; P = 0.04), and low‐density lipoprotein particle size (β = –0.27; P = 0.05) was independent of sex, body mass index, age, diabetes mellitus, time from transplant, and indication for LT. In conclusion, de novo hepatic steatosis after LT is associated with atherogenic lipoproteins and independent of traditional CVD risk factors. Liver Transpl 21:1395‐1402, 2015 . © 2015 AASLD.